CD19-CAR_Lenti

DRUG2 trials

Sponsors

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Ospedale Pediatrico Bambino Gesu

Conditions

Refractory Systemic Autoimmune DiseasesRelapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Diffuse Large B Cell Lymphoma or Primary Mediastinal B Cell Lymphoma

Phase 1

Anti-CD19 CAR T-Cell TherApy in Refractory Systemic Autoimmune DISeases - CATARSIS

RecruitingCTIS2024-511293-74-01

Fondazione Policlinico Universitario Agostino Gemelli IRCCSRefractory Systemic Autoimmune Diseases

Start: 2024-11-26Target: 8Updated: 2025-10-10

Phase I/II study of anti-CD19 Chimeric Antigen Receptor-Expressing T cells in pediatric patients affected by relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Diffuse Large B Cell Lymphoma (DLBCL) or Primary Mediastinal B Cell Lymphoma (PML)

RecruitingCTIS2024-519174-39-00

Ospedale Pediatrico Bambino GesuRelapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Diffuse Large B Cell Lymphoma or Primary Mediastinal B Cell Lymphoma

Start: 2021-02-15Target: 32Updated: 2025-01-14